Author:
Guazzo Alessandro,Longato Enrico,Morieri Mario Luca,Sparacino Giovanni,Franco-Novelletto Bruno,Cancian Maurizio,Fusello Massimo,Tramontan Lara,Battaggia Alessandro,Avogaro Angelo,Fadini Gian Paolo,Di Camillo Barbara
Abstract
AbstractPredicting the risk of cardiovascular complications, in particular heart failure hospitalisation (HHF), can improve the management of type 2 diabetes (T2D). Most predictive models proposed so far rely on clinical data not available at the higher Institutional level. Therefore, it is of interest to assess the risk of HHF in people with T2D using administrative claims data only, which are more easily obtainable and could allow public health systems to identify high-risk individuals. In this paper, the administrative claims of > 175,000 patients with T2D were used to develop a new risk score for HHF based on Cox regression. Internal validation on the administrative data cohort yielded satisfactory results in terms of discrimination (max AUROC = 0.792, C-index = 0.786) and calibration (Hosmer–Lemeshow test p value < 0.05). The risk score was then tested on data gathered from two independent centers (one diabetes outpatient clinic and one primary care network) to demonstrate its applicability to different care settings in the medium-long term. Thanks to the large size and broad demographics of the administrative dataset used for training, the proposed model was able to predict HHF without significant performance loss concerning bespoke models developed within each setting using more informative, but harder-to-acquire clinical variables.
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Santulli, G. Epidemiology of cardiovascular disease in the 21st century: Updated updated numbers and updated facts. J. Cardiovasc. Dis. Res. 1, 1 (2013).
2. Yach, D., Leeder, S. R., Bell, J. & Kistnasamy, B. Global chronic diseases. Science 307, 317 (2005).
3. Buddeke, J. et al. Trends in comorbidity in patients hospitalised for cardiovascular disease. Int. J. Cardiol. 248, 382–388 (2017).
4. Longato, E. et al. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res. Care 8, e001451 (2020).
5. Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Lond. Engl. 393, 31–39 (2019).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献